Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05699226 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Amplitude Titration to Improve ECT Clinical Outcomes

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 30, 2026 to Jan 1, 2027 Completion date: Jan 30, 2026 to Jan 1, 2028v11 Show 1 more changeShow less
    • Completion date: Jan 30, 2026 to Jan 1, 2028
  2. 2 versions Re-verified since Jan 3, 2025, no change to tracked fieldsv9-v10
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 1, 2023 to Sep 14, 2023v8 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2023 to Sep 14, 2023
  4. Start date: Sep 1, 2023 to Dec 1, 2023v7
  5. Start date: Aug 1, 2023 to Sep 1, 2023v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Jul 1, 2023 to Aug 1, 2023v5
  2. Start date: Mar 1, 2023 to Jul 1, 2023v4
  3. Start date: Feb 1, 2023 to Mar 1, 2023v3
  4. Eligibility criteria shortened, about 2 words Study title shortened, about 3 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency
Trial Details
NCT Number NCT05699226
Lead Sponsor University of New Mexico
Collaborators: National Institute of Mental Health (NIMH)
Conditions Depression, ECT, Cognitive Change
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov